Coverage for Colorectal Cancer (CRC)
Effective October 18, 2020, CMS Molecular Diagnostics Program has finalized a local coverage determination (LCD) to provide Medicare benefits for the serial use of the Signatera molecular residual disease (MRD) test in patients with stage II or III colorectal cancer (CRC).
Coverage for Cancer and Immunotherapy
CMS has also issued a draft LCD to provide expanded coverage for Signatera to detect molecular residual disease in patients with a history of cancer to monitor immunotherapy (IO) response.
Coverage for Cancers Outside of CRC and Immunotherapy
There is variable coverage for Signatera based on your individual insurance plan. If insurance denies the test, there will be no out of pocket charges to you. If insurance covers the test, then you will be responsible for the deductible and co-pay assigned to you by your insurance benefits.